| Chronic Obstructive Airway Disease
Dalisrep vs Ohtuvayre
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Daliresp vs Ohtuvayre with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOhtuvayre has a higher rate of injection site reactions vs Daliresp based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ohtuvayre but not Daliresp, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Daliresp
Ohtuvayre
At A Glance
Oral
Daily
PDE4 inhibitor
Oral inhalation
Twice daily
PDE3/PDE4 inhibitor
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
Dosing
Chronic Obstructive Airway Disease Maintenance dose: 500 mcg once daily, with or without food; an optional titration of 250 mcg once daily for the first 4 weeks may reduce discontinuation rates, but 250 mcg is not the effective therapeutic dose.
Chronic Obstructive Airway Disease 3 mg (one unit-dose ampule) twice daily, once in the morning and once in the evening, via oral inhalation using a standard jet nebulizer with a mouthpiece.
Contraindications
- Moderate to severe liver impairment (Child-Pugh B or C)
- Hypersensitivity to ensifentrine or any component of this product
Adverse Reactions
Most common (>=2%) Diarrhea, weight decreased, nausea, headache, back pain, influenza, insomnia, dizziness, decreased appetite
Serious Diarrhea, atrial fibrillation, lung cancer, prostate cancer, acute pancreatitis, acute renal failure
Postmarketing Hypersensitivity reactions (angioedema, urticaria, rash), gynecomastia
Most common (>=1%) Back pain, hypertension, urinary tract infection, diarrhea
Serious Paradoxical bronchospasm, psychiatric events including suicidality
Pharmacology
Roflumilast and its active metabolite (roflumilast N-oxide) are selective inhibitors of phosphodiesterase 4 (PDE4); inhibition of PDE4 leads to accumulation of intracellular cyclic AMP in lung tissue, which is thought to underlie its therapeutic action in COPD.
Ensifentrine is a dual inhibitor of PDE3 and PDE4 enzymes; inhibition results in accumulation of intracellular cAMP and/or cGMP, producing downstream bronchodilatory and anti-inflammatory signaling effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Daliresp
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Ohtuvayre
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Daliresp
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (7/8)
Ohtuvayre
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Daliresp
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Ohtuvayre
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Daliresp.
Cost estimate not availableAssistance Fund: Chronic Obstructive Pulmonary Disease (COPD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DalirespView full Daliresp profile
OhtuvayreView full Ohtuvayre profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.